Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study

Zaky, Mohamed S.; Elgamal, Emad Eldin A.; Abd Al Maksoud, Ayman A.; Mohamed, Dina H.; Elsaie, Mohamed L.

doi:10.1038/s41598-023-44757-5

Cited by 3 publications

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Cacciapuoti,

Potestio,

Gallo

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundNovel biologics targeting the IL23/T‐17 axis, such as tildrakizumab, have been developed to treat psoriasis. There is limited evidence on the use of tildrakizumab for the treatment of psoriasis in difficult‐to‐treat areas.ObjectiveOur aim was to evaluate the short‐term efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis and with the involvement of difficult‐to‐treat areas.MethodsA multicentric retrospective study was conducted on patients who initiated tildrakizumab between July 2022 and July 2023. Psoriasis Area and Severity Index (PASI), Psoriasis Scalp Severity Index (PSSI), Palmoplantar Psoriasis Area and Severity Index (ppPASI), and Nail Psoriasis Severity Index (NAPSI) were measured at baseline and after 16 weeks. The percentages of achieving a PASI75, PASI90, or PASI100 response were assessed. Dermatology Life Quality Index (DLQI) and Itch Visual Analog Scale (VAS) were measured simultaneously. Data about potential safety issues and adverse events were collected.ResultsA total of 76 patients were included, and 59 (77.6%) were affected by psoriasis localized to the scalp (n = 32), palmoplantar locations (n = 13), or nails (n = 14). The mean PASI score decreased from 16.5 ± 9.8 at baseline to 1.9 ± 1.6 after 16 weeks. Tildrakizumab treatment resulted in the improvement of PSSI (19.9 ± 10.7 to 2.7 ± 4.2), ppPASI (15.4 ± 6.9 to 1.9 ± 2.3), and NAPSI (20.3 ± 16.9 to 7.6 ± 10.8) from baseline to 16 weeks, respectively. DLQI and Itch VAS also showed marked improvement.ConclusionsTildrakizumab is a valuable option for treating difficult‐to‐treat psoriasis and pruritus, with rapid onset of action.

show abstract

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Cacciapuoti,

Potestio,

Gallo

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Association Between Psoriasis and Sleep Quality Among US Adults: National Health and Nutrition Examination Survey 2009-2014

Fu,

Zhou,

et al. 2024

Preprint

View full text Add to dashboard Cite

Current research has been restricted in furnishing nationally representative data regarding the association between psoriasis and sleep quality in US adults. To fill this gap, we conducted a cross-sectional study using data from National Health and Nutrition Examination Survey (NHANES) 2009–2014. We identified 376 (2.83%) cases of psoriasis and 3,615 (29.1%) cases of sleep disorder among 13,002 US adult citizens in present study. The results showed that that psoriasis was significantly associated with sleep disorder in US adults (OR, 1.71; 95% CI, 1.36–2.14), and the association remained in fully adjusted model (OR, 1.46; 95% CI, 1.15–1.86). We also conducted several sensitivity analyses (including IPTW) to access the robustness of our findings. Interestingly, we found that there is no significant association between psoriasis and sleep duration. These findings may be important to consider the poor sleep quality may be exacerbate the psoriasis. Our findings may contribute to future clinical management of sleep quality in psoriasis patients.

show abstract

Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review

Modarresi Chahardehi,

Ojaghi,

Motedayyen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Psoriasis, a persistent immune-mediated inflammatory skin condition, affects approximately 2-3% of the global population. Current treatments for psoriasis are fraught with limitations, including adverse effects, high costs, and diminishing efficacy over time. Thymoquinone (TQ), derived from Nigella sativa seeds, exhibits promising anti-inflammatory, antioxidant, and immunomodulatory properties that could prove beneficial in managing psoriasis. However, TQ’s hydrophobic nature and poor bioavailability have hindered its usefulness as a therapeutic agent. Recent research has strategically addressed these challenges by developing nano-thymoquinone (nano-TQ) formulations to enhance delivery and efficacy in treating psoriasis. Preclinical studies employing mouse models have demonstrated that nano-TQ effectively mitigates inflammation, erythema, scaling, epidermal thickness, and cytokine levels in psoriatic lesions. Various nano-TQ formulations, including nanoemulsions, lipid vesicles, nanostructured lipid carriers, and ethosomes, have been explored to improve solubility, facilitate skin penetration, ensure sustained release, and achieve site-specific targeting. Although clinical trials are currently scarce, the outcomes from in vitro and animal models are promising. The potential co-delivery of nano-TQ with other anti-psoriatic agents also presents avenues for further investigation.

show abstract

Evaluation of sleep quality and pruritus severity in psoriatic patients and their impact on quality of life: a cross section correlational study

Cited by 3 publications

References 36 publications

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience

Association Between Psoriasis and Sleep Quality Among US Adults: National Health and Nutrition Examination Survey 2009-2014

Nano-based formulations of thymoquinone are new approaches for psoriasis treatment: a literature review

Contact Info

Product

Resources

About